April 24, 2017
Stemming from the INTREPID Trial, three recently published papers give credence to pitavastatin’s ability to lower cholesterol and dampen inflammation in people living with HIV. While the results demonstrate the unique effects of pitavastatin in HIV and underscore its position as a promising cardiovascular disease (CVD) prevention strategy, they also highlight the need for the REPRIEVE Trial to determine whether pitavastatin prevents cardiovascular disease events, such as heart attacks and strokes. Read more here: http://bit.ly/2oYg74P
